anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition for treating or preventing cancer or human immunodeficiency virus(HIV) is provided to inhibit AKT activation, suppress phosphoinisitide 3-kinase(PI3K), and beta activate glycogen synthase kinase 3 beta(GSK3). CONSTITUTION: A composition for treating or preventing human immunodeficiency virus(HIV), HIV infection, HIV dementia, and cancer comprises kalopanaxsaponin A as an active ingredient. The human immunodeficiency virus infection is a latent infection. The human immunodeficiency virus infection is macrophage or microglia cell infection. A food composition for treating and preventing HIV infection, acquired immune deficiency syndrome(AIDS), HIV nerve cell damage, and HIV dementia comprises kalopanaxsaponin A as an active ingredient. A pharmaceutical composition for treating and preventing cancer comprises kalopanaxsaponin A as an active ingredient. A food composition for treating and preventing cancer comprises kalopanaxsaponin A as an active ingredient.
Erythropoietin or Erythropoiesis-Stimulating Agent (ESA) for use in treating bone inflammation or bone infection or Osteomyelitis. An effective dosage of Erythropoietin or ESA is administered to a human subject via: subcutaneous injection, intravenous injection, subcutaneous administration, intravenous administration, subcutaneous implant, oral delivery, or a combination thereof. The dosage is in a range of 3,000 to 10,000 units per administration session, or 4,000 to 6,000 units per administration session. The administration frequency is 2 or 3 times per week, for a period of at least 6 weeks. Optionally, an antibiotic agent is also administered, concurrently or prior to or after the administration of the Erythropoietin or ESA. Particularly, the human subject is non- Anemic, and is not or was not diagnosed with Anemia, and did not or does not suffer from Anemia. Optionally, the administration of Erythropoietin or EP A may prevent limp amputation, particularly for a diabetic subject.
INTRODUCTION: There has been increased interest in using autologous tissues since the Food and Drug Administration banned transvaginal mesh for pelvic organ prolapse in 2019. Our study aims to assess patients' perspective of functional and cosmetic impact on the fascia lata harvest site in patients undergoing fascia lata harvest for the treatment of stress urinary incontinence (SUI).
METHODS: This is a prospective survey study of a retrospective cohort of patients who underwent a fascia lata pubovaginal sling between 2017 and 2022. Participants completed a survey regarding the functional and cosmetic outcomes of the harvest site.
RESULTS: Seventy-two patients met the inclusion criteria. Twenty-nine patients completed the survey for a completion rate of 40.3%. For functional symptoms, 24.1% (7/29) of patients reported leg discomfort, 10.3% (3/29) reported leg weakness, 10.3% (3/29) reported a bulge, 17.2% (5/29) reported scar pain, 14.8% (4/27) reported scar numbness, and 17.2% (5/29) reported paresthesia at the scar. For cosmetic outcomes, 72.4% (21/29) reported an excellent or good scar appearance. On the PGI-I, 75.9% (22/29) reported their condition as very much better (48.3%, 14/29) or much better (27.6%, 8/29).
CONCLUSIONS: The majority of patients reported being satisfied with the functional and cosmetic outcomes of their harvest site as well as satisfied with the improvement in their SUI. Less than 25% of patients report harvest site symptoms, including leg weakness, scar bulging, scar pain, scar numbness, or paresthesia in the scar. This is important in the context of appropriate preoperative discussion and counseling regarding fascia lata harvest.
BACKGROUND: Gastrointestinal bleeding (GIB) is a common complication of intracerebral hemorrhage (ICH). Rate pressure product (RPP) is an objective hemodynamic index that is closely related to the prognosis of cardia-cerebrovascular disease. The purpose of this study was to investigate the relationship between RPP and GIB in ICH patients.
METHODS: We retrospectively analyzed data from ICH patients admitted to the neurosurgery department of Nanchang University affiliated with Ganzhou Hospital from January 2019 to December 2021. The patients were divided into a GIB group and a non-GIB group according to whether they had GIB. Propensity score matching was used to match between the two groups. Univariate analysis was used to select factors affecting GIB, and multivariate conditional logistic regression was used to analyze the independent factors associated with GIB.
RESULTS: There were 1232 patients included in the study, including 182 in the GIB group and 1050 in the non-GIB group, and 182 pairs of patients were successfully matched through propensity score matching. The univariate analysis showed that high RPP, low Glasgow coma score (GCS), fibrinogen, D-dimer and PPIs were factors associated with GIB. Multivariate conditional logistic regression showed that high RPP, low GCS and urokinase were independent risk factors for GIB, and PPIs was a protective factor for GIB.
CONCLUSIONS: High RPP, low GCS and urokinase were independent risk factors for GIB, and PPIs was a protective factor for GIB. Patients with a high risk of developing GIB should be monitored closely. Nevertheless, multicenter prospective studies with more patients are needed to further validate the results.
BACKGROUND: While diarrhoeal disease remains a leading cause of death in children aged <5 years in low- and middle-income countries (LMICs), it also poses significant health risks for older children, underscoring the importance of our study focusing on children aged <10 years. In this systematic review, we assessed common diarrhoea aetiologies in children aged <10 years in LMICs.
METHODS: We identified relevant articles in PubMed, Embase, and Web of Science using pre-defined search criteria. We included case series and case-control studies of children aged <10 years with non-bloody, bloody, acute, persistent, and chronic diarrhoea. Articles that evaluated two or more diarrhoea pathogens in LMICs conducted between 1 January 1990 and 31 July 2020 were eligible for inclusion. We stratified combined data from case series and case-control studies by age and World Health Organization (WHO) regions.
RESULTS: 76 studies published between 1990-2020 were eligible for inclusion. Among these, eight were case-control studies. 56 papers focused only on children aged <5 years, while 20 also included children aged ≥5 years. The most common viral pathogens among <5 years old children were rotavirus, norovirus, adenovirus, and astrovirus. Bacterial pathogens included Escherichia coli, Salmonella enterica, Shigella species, and Campylobacter species, while parasitic pathogens included Cryptosporidium, Giardia, and Entamoeba species. Rotavirus was the most common viral pathogen among children across all age groups and every WHO region. Escherichia coli was prevalent in all age groups and was responsible for most diarrhoea cases in the African Region. Among parasitic pathogens, Entamoeba species and Giardia were prevalent in children aged three to five years, with the former a major cause of diarrhoea in the Eastern Mediterranean Region. Similarly, in children aged six to 10 years, bacterial pathogens, including Escherichia coli, Salmonella, and Shigella, suggest a continued significance of these pathogens beyond the age of five. Common viral pathogens for this group were rotavirus, norovirus, and sapovirus, although the number of studies for this age group is limited.
CONCLUSIONS: Escherichia coli, rotavirus, and Entamoeba species were the most common pathogens responsible for diarrhoea in children aged <5 years in LMICs. Future research should focus on characterising the pathogens responsible for causing diarrhoea in children aged six to 10 years stratified by geographic area of residence, i.e. WHO region and urban vs rural. Case-control or cohort studies covering a full 12-month period to account for seasonality are needed for a more accurate picture of diarrhoea aetiology among children.
REGISTRATION: PROSPERO (CRD42020204005).
Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus and stomach through your nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus. Proper placement of the catheters will be determined using normal tidal breathing against an occluded mouthpiece with a nose clip. Once proper placement is ensured, the catheters will remain in place during your normal PFT maneuvers. Additionally, while the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a distal pressure measurement catheter to measure airway pressure. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
This trial is a single arm, prospective study of the safety and effectiveness of eCoin tibial nerve stimulation in 25 subjects with refractory overactive bladder as defined by the American Urological Association.. The eCoin neuromodulation device will be implanted subcutaneously in the right or left leg of patients with urgency urinary incontinence. After a 4 week implant healing period, subjects will have their devices activated (turned ON). After 3 months of device therapy (occurring 4 months post-implant), the primary endpoint will be assessed. It is anticipated that subjects will reach the full therapeutic effect at approximately 3 months of therapy. Subjects will be followed for an additional 9 months to assess the safety of maintenance stimulation therapy with fewer sessions occurring during this time interval.
The application provides a traditional Chinese medicine cold compress patch which comprises ginseng, frankincense, myrrh, chinese angelica, szechuan lovage rhizome, divaricate saposhnikovia root, mugwort leaf, red paeony root and safflower. The mass ratio of the radix sileris to the folium artemisiae argyi is in the range of 0.8-1. The ginseng comprises, by mass, 30-32 parts of ginseng, 80-82 parts of frankincense, 70-75 parts of myrrh, 30-32 parts of angelica sinensis, 32-35 parts of ligusticum wallichii, 24-30 parts of radix sileris, 28-32 parts of mugwort leaf, 44-45 parts of red paeony root and 30-32 parts of safflower. Also comprises a hydrogel layer and a supporting cloth layer. Also comprises a hydrogel layer and a supporting cloth layer. The traditional Chinese medicine cold compress patch is suitable for bone joint discomfort, swelling, arthralgia and muscle ligament injury caused by qi and blood obstruction and meridian obstruction, and can improve cervical vertebra.
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use zolmitriptan tablets for a condition for which they were not prescribed. Do not give zolmitriptan tablets to other people, even if they have the same symptoms as you. People may be harmed if they take medicines that have not been prescribed for them. 

This leaflet summarizes the most important information about zolmitriptan tablets. If you would like more information about zolmitriptan tablets, talk to your doctor. You can ask your doctor or pharmacist for information on zolmitriptan tablets that is written for healthcare professionals. 

You can also call Avema Pharma Solutions at 1-877-753-3935
PURPOSE: Sequential working memory is the ability to maintain and manipulate sequential information at a second time scale. Patients with progressive supranuclear palsy (PSP) or Parkinson's disease (PD) perform poorly in tests that require the flexible arrangement of thoughts or actions. This study investigated whether sequential working memory is differently impaired in patients with PSP versus PD.
METHOD: Twenty-nine patients with PSP Richardson's syndrome (PSP-RS), 36 patients with PD, and 36 healthy controls (HC) completed 3 well-established neuropsychological tests, including digit span forward (DST-F), digit span backward (DST-B), and adaptive digit ordering tests (DOT-A). The DST-F required maintaining digit sequences, and the DST-B and DOT-A required maintaining and manipulating digit sequences.
FINDING: The PSP-RS group scored lower than the PD and HC groups in the DST-B and DOT-A but not in the DST-F, indicating that the ability to manipulate sequences was impaired, but the maintenance ability was preserved in PSP-RS patients. Moreover, in PSP-RS, the DST-B score negatively correlated with the severity of motor symptoms. The actual levodopa dose positively correlated with the DST-B ordering cost (DST-F score vs. DST-B score). The PSP patients who took a greater dose of levodopa tended to have higher DST-B ordering cost. There was no effect of levodopa on DST-B or DOT-A in PD.
CONCLUSION: These results suggested that the ability to manipulate sequence was already reduced in patients with PSP-RS and was worse than in patients with PD.
PURPOSE:To provide a hypocholesteric agent containing tocopherol-enriched poultry egg as an active component and effective to remarkably decrease the total serum cholesterol and HDL-cholesterol, etc., compared with an egg simply added with tocopherol. CONSTITUTION:For example, a commercially available formula feed for laying hen is added with a deodorization distillate of refined soybean (tocopherol- contents, alpha 2.23%, beta 0.16%, gamma 9.96% and delta 3.12%; free fatty acid content, 21%) in an amount of 1.5% to obtain a feed having a VE value of 940. A Highline- breed laying hen is fed continuously with said feed and the laid egg is used as a tocopherol-enriched egg. The total tocopherol content in the yolk of the egg is >=50mg%. The enriched egg exhibits remarkable lipid-metabolizing effect compared with an egg added simply with tocopherol. The egg is compounded to foods, drinks, medicines or formula feed for animal to decrease the cholesterol level of man and domestic animal.
BACKGROUND & AIMS: With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C.
METHODS: 424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman's correlation and AUROC analyses.
RESULTS: Data of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman's rho = 0.39 and rho = 0.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65-0.83), and 0.67(95%CI 0.56-0.78) for the discrimination of F3/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests.
CONCLUSIONS: sST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.
BACKGROUND: This study employed integrated network pharmacology approach to explore the mechanisms underlying the protective effect of colchicine against acute lung injury (ALI).
METHODS: We analyzed the expression profiles from 13 patients with sepsis-related ALI and 21 controls to identify differentially expressed genes and key modules. ALI-related genes were curated using databases such as DisGeNET, Therapeutic Target, and Comparative Toxicogenomics Database to curate ALI-related genes. Drug target fishing for colchicine was conducted using the DrugBank, BATMAN-TCM, STITCH, and SwissTargetPrediction. Potential drug-disease interactions were determined by intersecting ALI-associated genes with colchicine target genes. We performed comprehensive pathway and process enrichment analyses on these genes. A protein-protein interaction network was constructed, and topological analysis was executed. Additionally, an ALI mouse model was established to evaluate the effect of colchicine on CXCL12 and CXCR4 levels through western blot analysis.
RESULTS: Analysis revealed 23 potential colchicine-ALI interaction genes from the intersection of 253 ALI-associated genes and 389 colchicine targets. Functional enrichment analysis highlighted several inflammation-related pathways, such as cytokine-mediated signaling pathway, CXCR chemokine receptor binding, NF-kappa B signaling pathway, TNF signaling pathway, and IL-17 signaling pathway. The protein-protein interaction network demonstrated complex interactions for CXCL12 and CXCR4 among other candidate genes, with significant topological interaction degrees. In vivo studies showed that colchicine significantly reduced elevated CXCL12 and CXCR4 levels in ALI mice.
CONCLUSION: Our findings suggest that colchicine's therapeutic effect on ALI might derive from its anti-inflammatory properties. Further research is needed to explore the specific mechanisms of colchicine's interaction with sepsis-induced ALI.
The present invention relates to nucleic acid molecules coding for proteins, isoforms of said proteins or mutant forms of said proteins whereby the level of expression of said proteins is connected with retinal diseases. Assessment of the expression level of proteins encoded by said nucleic acid molecules or corresponding mRNAs may be used for testing the predisposition of mammals and preferably humans of a retinal disease or for an acute state of such a disease. Preferred diseases in accordance with the invention are macular degeneration and more preferably AMD. The present invention further relates to methods of identifying compounds capable of normalizing the expression level of the aforementioned genes and of further genes affected by the abnormal expression. The identified compounds may be used for formulating compositions, preferably pharmaceutical compositions for preventing or treating retinal diseases. They may also be used as lead compounds for the development of medicaments having an improved efficiency, a longer half-life, a decreased toxicity etc. and to be employed in the treatment of retinal diseases. Included in the invention are also somatic gene therapy methods comprising the introduction of at least one functional copy of any of the above-mentioned genes into a suitable cell. Finally, the invention relates to non-human transgenic animals comprising at least one of the aforementioned genes in their germ line. The transgenic animals of the invention may be used for the development of medicaments for the treatment of retinal diseases. Finally, the present invention relates to diagnostic kits useful in the diagnosis of the aforementioned diseases.
GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
PURPOSE: A composition containing gastrodin and glucosidase for skin whitening is provided to ensure high whitening effect and to minimize side effects by formulation unstability and skin irritation. CONSTITUTION: A composition for skin whitening contains gastrodin and glucosidase as an active ingredient. Gastrodin is an alpha-gastrodin prepared by binding 1-8 alpha-D-glucoses by transglycosylation reaction using beta-gastrodin of chemical formula 1 or cyclodextrin glycosyltransferase. The gastrodin content is 0.01-10.0 weight% based on total composition. The glucosidase content is 75-150 units based on 3 weight% of gastrodin. The beta-gastrodin is a natural gatrodin or synthetic gastrodin. The natural gastrodin is isolated from Gastrodiae Rhizoma.
Previous studies have investigated the health hazards caused by exposure to the noise of heavy equipment used at construction sites. Korea's Ministry of Land, Infrastructure, and Transport operates a registration system for construction machinery, and regular safety inspections are mandatory. Although workers inspecting construction machinery vehicles are exposed to unwanted noise, no noise exposure assessment has been made regarding these workers in Korea. The time-weighted average (TWA) daily average noise exposure level among construction machinery inspectors at 18 inspection centers was 75.3 dB(A). Among the inspection steps, the exhaust gas inspection step was found to exhibit the highest noise exposure level, up to 100 dB(A). In Korea, if the noise level of a workplace exceeds 85 dB(A) as a TWA, workers are required to undergo special medical examinations. This study found that special medical examinations were required for two of the 18 target inspection centers (approximately 115 workers) as the 8-hour TWA noise level exceeded 85 dB(A). Therefore, regular noise exposure assessment and special medical examinations for noise are required to prevent inspectors from developing hearing disorders due to noise exposure.
PURPOSE:To obtain an amylase inhibitor, consisting essentially of a leaf or a deoiled leaf of a laurel tree and excellent in activity without any problems in safety and effectiveness. CONSTITUTION:The objective amylase inhibitor is obtained by intactly using a leaf in a raw or a dry state in its intact shape obtained from a laurel tree which is an evergreen tree or finely cutting the leaf, roughly crushing or pulverizing the leaf and powdering the leaf for use. The leaf of the laurel tree is defatted with an oil-soluble organic solvent such as hexane or defatted by steam treatment such as steam distillation or treatment in an autoclave. The amylase inhibitor consisting essentially of the leaf of the laurel tree as an active ingredient in an amount of 0.3-15wt.% can be included to provide a pharmaceutical. The inhibitor in an amount of 0.001-100wt.% can be blended in a food, especially a food (e.g. bread or noodle) containing a glucide such as starch.
FIELD: food industry; pharmaceutics.SUBSTANCE: group of inventions refers to preservation of pharmaceutical, nutraceutical and food products including microorganisms due to provision of microorganisms viability in specified products. Group of inventions includes a dry stable composition and a method for production thereof. Composition contains one or more viable microorganisms, at least 50 wt % of one or more hydrolysed proteins and less than 5 wt % of one or more sugars selected from a group consisting of monosaccharides, disaccharides and combinations thereof, all percentages being based on the total weight of the dry composition. Preferably, the composition does not contain a monosaccharide or disaccharide. Composition can additionally contain one or more oligosaccharides, one or more polysaccharides, one or more salts of carboxylic acid or their combination. Pot life of the composition can be at least 1×10 CFU/g, loss of viability less than 1 log CFU/g in 3 months at temperature 40 °C and relative humidity of 33 %. Also disclosed is a method of producing a dry stable composition.EFFECT: inventions provide the possibility of long-term storage of products and pharmaceutical agents containing microorganisms.22 cl, 2 dwg, 18 ex, 2 tbl